Amicogen (092040) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, Amicogen (092040) reported revenue of 42.0 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202542.0 billion KRW-17.1 billion KRW-30.4 billion KRW[source]
2024173.6 billion KRW-7.1 billion KRW-50.9 billion KRW[source]
2023159.9 billion KRW2.1 billion KRW-20.7 billion KRW[source]
2022144.3 billion KRW-4.9 billion KRW-45.8 billion KRW[source]
2021124.9 billion KRW-4.6 billion KRW4.7 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025197.5 billion KRW86.3 billion KRW111.1 billion KRW[source]
2024261.4 billion KRW131.3 billion KRW130.0 billion KRW[source]
2023306.1 billion KRW130.4 billion KRW175.7 billion KRW[source]
2022282.5 billion KRW156.7 billion KRW125.8 billion KRW[source]
2021283.7 billion KRW100.1 billion KRW183.6 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice